Bio-Techne Corp. - $TECH STOCK NEWS

Bio-Techne (NASDAQ: TECH) will present at the 27th Annual Meeting of the American Society of Gene & Cell Therapy, showcasing its cell and gene therapy workflow solutions. The event will feature speaker sessions, poster presentations, and a multimedia experience highlighting Bio-Techne's innovative tools and solutions for advancing cell and gene therapies.

Bio-Techne (NASDAQ: TECH) reported third-quarter fiscal 2024 results with organic revenue up 2%, GAAP EPS at $0.31, adjusted EPS at $0.48, and strong commercial execution in Diagnostics & Genomics segment. Cash flow increased by 31% to $223.5 million.

Bio-Techne (NASDAQ: TECH) declared a quarterly dividend of $0.08 per share for the quarter ended March 31, 2024. The dividend will be payable on May 24, 2024, to common shareholders of record on May 13, 2024. The company is a global life sciences provider of tools and bioactive reagents for research and clinical diagnostics, generating $1.1 billion in net sales in fiscal 2023.

Bio-Techne appointed Dr. Judith Klimovsky as an independent director on the Board of Directors, bringing valuable experience from the biotechnology industry. Dr. Klimovsky's background in antibody therapeutics and global clinical development positions her well to contribute to Bio-Techne's expansion efforts. The addition of Dr. Klimovsky enhances the board's expertise and diversity, with a focus on Latin America and global biopharma.

Bio-Techne (NASDAQ: TECH) has announced a new distribution agreement with Thermo Fisher Scientific, effective May 1, 2024. This strategic partnership will see Thermo Fisher distributing Bio-Techne's innovative products across Europe, enhancing support for researchers and accelerating scientific discoveries. The collaboration aims to empower scientists in areas such as cell and gene therapy, immunology, and neuroscience, ultimately advancing healthcare outcomes. Thermo Fisher's dedication to fostering innovation and collaboration within the scientific community is highlighted through this partnership.

Bio-Techne (NASDAQ: TECH) and Novomol-Dx have developed the Bio-Marker Pathfinder (BMP), a groundbreaking ocular biomarker kit for point-of-care application. The kit, running on Bio-Techne's Ella™ platform, provides accurate, reliable data in less than 90 minutes, targeting Dry Eye Disease, Diabetic Retinopathy, and patient monitoring post-ocular surgeries. With potential applications beyond ocular diseases, the BMP kit addresses a significant unmet need in India, aiming to benefit millions of patients. The partnership between Bio-Techne and Novomol-Dx showcases the potential of biomarker research in diagnostic and prognostic applications, promising a brighter future for ocular healthcare.

Bio-Techne (NASDAQ: TECH) has filed a patent infringement lawsuit against Molecular Instruments, Inc. in Europe to protect its patented RNAscope® ISH technology. The lawsuit alleges that Molecular Instruments' HCR 3.0 technology infringes ACD's European Patents 1,910,572 and 2,500,439. Bio-Techne aims to halt the infringement, seek damages, and obtain injunctive relief in key European markets to defend its position as a global leader in spatial biology research and clinical applications.

Bio-Techne (NASDAQ: TECH) will host a conference call on May 1, 2024, to review third quarter fiscal 2024 financial results. Bio-Techne is a leading developer of high-quality purified proteins, reagent solutions, and diagnostic products.

Bio-Techne (NASDAQ: TECH) announces that Advanced Cell Diagnostics (ACD) has reached a milestone of over 10,000 peer-reviewed publications utilizing RNAscope™ ISH technology, solidifying its leadership in spatial biology applications. The increasing global customer awareness and market adoption signify ACD's significant impact in enabling ground-breaking biologic discoveries and therapeutic advancements.